Connect Biopharma Holdings Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Barry Quart
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01CEO
Barry Quart (67 yo)
less than a year
Tenure
Dr. Barry D. Quart, Pharm D., serves as Chief Executive Officer & Director of Connect Biopharma Holdings Limited since June 12, 2024. He had served as Chief Executive Officer of Heron Therapeutics, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| President | less than a year | no data | no data | |
| General Counsel & Chief Compliance Officer | 3.3yrs | no data | no data | |
| VP of Biologics & Head of CMC | 4.9yrs | no data | no data | |
| VP & Global Head of Medical Affairs | no data | no data | no data | |
| Senior Vice President of Clinical Development(Consultant) | less than a year | no data | no data |
0.9yrs
Average Tenure
60yo
Average Age
Experienced Management: CNTB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Director | 3.3yrs | no data | 0% $ 0 | |
| Independent Non-Executive Director | 4yrs | no data | 0.018% $ 12.7k | |
| Independent Chairman | 4yrs | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data |
3.9yrs
Average Tenure
63.5yo
Average Age
Experienced Board: CNTB's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 23:44 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Connect Biopharma Holdings Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Ziyu He | China International Capital Corporation Limited |
| Emily Bodnar | H.C. Wainwright & Co. |